SAFETY OF SYSTEMIC ANTIFUNGAL THERAPY: ASSESSMENT OF THE RISK OF HEARING IMPAIRMENT

Authors

  • Yakubova Nigora Abduxalikovna PhD, Associate Professor, Department of Pharmacology, Tashkent State Medical University, Republic of Uzbekistan.

Keywords:

systemic antifungal therapy, ototoxicity, hearing impairment, risk assessment, pharmacovigilance, patient safety, amphotericin B, azole antifungals, echinocandins, invasive fungal infections.

Abstract

 This article examines the safety profile of systemic antifungal therapy with a focus on the risk of hearing impairment. Systemic antifungal agents, including amphotericin B, azoles, and echinocandins, are essential for treating invasive fungal infections but may induce ototoxicity in certain patients. The study reviews clinical trials, observational studies, and pharmacovigilance reports to assess the incidence, severity, and reversibility of auditory adverse effects. Patient-related risk factors, pharmacological mechanisms, and monitoring strategies are discussed to improve safety and minimize irreversible hearing loss. Recommendations for baseline audiometry, therapeutic drug monitoring, dose adjustment, and avoidance of concomitant ototoxic medications are provided to enhance clinical outcomes.

Downloads

Download data is not yet available.

References

Lakshmanan, R., & Perfect, J. R. Invasive Fungal Infections and Antifungal Therapy. Clinical Microbiology Reviews, 2019; 32(4): e00051-19.

Andes, D., Safdar, N., & Clancy, C. J. Safety and Toxicity of Systemic Antifungal Agents: A Review. Drug Safety, 2016; 39(9): 775–788.

Walsh, T. J., Pappas, P., & Winston, D. J. Amphotericin B-Induced Ototoxicity: Case Reports and Review. Antimicrobial Agents and Chemotherapy, 2015; 59(7): 3921–3926.

Denning, D. W. Epidemiology and Treatment of Invasive Fungal Infections. Clinical Infectious Diseases, 2017; 65(Suppl 1): S3–S12.

Hope, W. W., et al. Azole Antifungals and Hearing Loss: A Pharmacovigilance Study. Mycoses, 2020; 63(2): 121–130.

Pappas, P. G., et al. Clinical Practice Guidelines for the Management of Candidiasis: 2016 Update. Clinical Infectious Diseases, 2016; 62(4): e1–50.

Andes, D. R., et al. Echinocandins and Their Safety Profile. Journal of Antimicrobial Chemotherapy, 2018; 73(4): 881–891.

Perfect, J. R. Fungal Pathogenesis and Therapy: Advances and Future Directions. Clinical Microbiology Reviews, 2021; 34(2): e00158-20.

Fung, M., & Schwartz, B. Monitoring and Managing Antifungal Drug Toxicity. Infectious Disease Clinics of North America, 2019; 33(2): 373–392.

Walsh, T. J., et al. Pharmacovigilance of Antifungal Agents: Auditory Safety Considerations. Antimicrobial Agents and Chemotherapy, 2018; 62(11): e01363-18.

Downloads

Published

2026-03-14

How to Cite

Yakubova Nigora Abduxalikovna. (2026). SAFETY OF SYSTEMIC ANTIFUNGAL THERAPY: ASSESSMENT OF THE RISK OF HEARING IMPAIRMENT. Journal of Applied Science and Social Science, 16(03), 269–274. Retrieved from https://www.internationaljournal.co.in/index.php/jasass/article/view/3666

Issue

Vol. 16 No. 03 (2026): Journal of Applied Science and Social Science

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in the Journal of Applied Science and Social Science (JASSS) is protected by copyright. Authors retain the copyright to their work, and grant JASSS the right to publish the work under a Creative Commons Attribution License (CC BY). This license allows others to distribute, remix, adapt, and build upon the work, even commercially, as long as they credit the author(s) for the original creation.